Published in Clin Appl Thromb Hemost on July 01, 2003
Effect of Apple Flavanols on Risk of Cardiovascular Disease (FLAVO) | NCT00568152
Evaluation of the mean platelet volume in patients with cardiac syndrome X. Clinics (Sao Paulo) (2012) 2.34
Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia (2010) 2.10
A genome-wide association study identifies three loci associated with mean platelet volume. Am J Hum Genet (2008) 1.81
Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag (2010) 1.26
Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int (2011) 1.12
Predictive role of hematologic parameters in testicular torsion. Korean J Urol (2015) 1.05
K(3)EDTA Vacuum Tubes Validation for Routine Hematological Testing. ISRN Hematol (2012) 0.95
Value of serial platelet indices measurements for the prediction of pulmonary embolism in patients with deep venous thrombosis. Ther Clin Risk Manag (2015) 0.83
Assessment of the relation between mean platelet volume, non-dipping blood pressure pattern, and left ventricular mass index in sustained hypertension. Med Sci Monit (2014) 0.81
Platelet-larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization. Heart Vessels (2013) 0.80
Is mean platelet volume really a severity marker for obstructive sleep apnea syndrome without comorbidities? Pulm Med (2014) 0.79
The correlation between red blood cell distribution width levels with the severity of obstructive sleep apnea and carotid intima media thickness. Med Sci Monit (2014) 0.78
Mean platelet volume is associated with disease severity in patients with obstructive sleep apnea syndrome. Clinics (Sao Paulo) (2015) 0.78
Altered mean platelet volume in patients with polymyositis and its association with disease severity. Braz J Med Biol Res (2016) 0.78
Blood count parameters can predict the severity of coronary artery disease. Korean J Intern Med (2016) 0.77
Dok-2 adaptor protein regulates the shear-dependent adhesive function of platelet integrin αIIbβ3 in mice. J Biol Chem (2014) 0.76
The platelet-to-lymphocyte ratio reflects the severity of obstructive sleep apnea syndrome and concurrent hypertension. Clin Hypertens (2016) 0.75
Can mean platelet volume be used as a biomarker for asthma? Postepy Dermatol Alergol (2016) 0.75
Complete blood count alterations after six months of continuous positive airway pressure treatment in patients with severe obstructive sleep apnea. J Clin Sleep Med (2014) 0.75
An Increase in Mean Platelet Volume/Platelet Count Ratio Is Associated with Vascular Access Failure in Hemodialysis Patients. PLoS One (2017) 0.75
Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis. Sci Rep (2017) 0.75
Value of platelet indices in identifying complete resolution of thrombus in deep venous thrombosis patients. Indian J Hematol Blood Transfus (2014) 0.75
Mean platelet volume: a potential biomarker of the risk and prognosis of heart disease. Korean J Intern Med (2016) 0.75
Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease. Oncotarget (2017) 0.75
Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des (2011) 4.16
A review of drug-induced hyponatremia. Am J Kidney Dis (2008) 2.97
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother (2012) 2.01
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation (2004) 1.91
Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant (2006) 1.90
Time for new indications for statins? Med Sci Monit (2009) 1.87
Association of Helicobacter pylori infection with cardiovascular disease--is it just a myth? Eur J Intern Med (2010) 1.67
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin (2010) 1.56
Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. J Psychosom Res (2010) 1.54
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Comparison of the five 2011 guidelines for the treatment of carotid stenosis. J Vasc Surg (2012) 1.51
Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med (2002) 1.49
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis? Angiology (2009) 1.47
The role of Toll-like receptors in renal diseases. Nat Rev Nephrol (2010) 1.42
Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology (2012) 1.40
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem (2005) 1.40
Optimal statin type and dosage for vascular patients. J Vasc Surg (2011) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg (2007) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol (2011) 1.27
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
A review of drug-induced hypocalcemia. J Bone Miner Metab (2009) 1.23
Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol (2008) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
Apolipoprotein E and renal disease. Am J Kidney Dis (2004) 1.20
The prevalence of metabolic syndrome in various populations. Am J Med Sci (2007) 1.19
Drug-induced fibrotic valvular heart disease. Lancet (2009) 1.19
Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'. Clin Cardiol (2013) 1.14
Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications (2008) 1.14
Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med (2011) 1.14
Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol (2010) 1.14
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis (2006) 1.12
Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int (2011) 1.12
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
Vascular risk factors in South Asians. Int J Cardiol (2008) 1.11
Prediabetes: to treat or not to treat? Eur J Pharmacol (2011) 1.11
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (2010) 1.10
HSP 70 and atherosclerosis--protector or activator? Expert Opin Ther Targets (2009) 1.10
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Lone atrial fibrillation: what do we know? Heart (2009) 1.08
Clinical relevance of postprandial lipaemia. Curr Med Chem (2005) 1.08
Pleiotropic effects of statins--clinical evidence. Curr Pharm Des (2009) 1.08
The effect of smoking on arterial stiffness. Hypertens Res (2010) 1.07
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis (2012) 1.06
Serum uric acid as an independent predictor of early death after acute stroke. Circ J (2007) 1.06
Statins: a sine qua non of the management of patients with abdominal aortic aneurysms. Int J Cardiol (2013) 1.06
Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J (2011) 1.06
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol (2007) 1.05
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf (2008) 1.05
Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP (2003) 1.04
An update on biomarkers of heart failure in hypertensive patients. J Hypertens (2012) 1.04
Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol (2013) 1.04
The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res (2009) 1.03
Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem (2003) 1.03
Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol (2010) 1.03
Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism (2006) 1.02
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother (2011) 1.01
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01
Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des (2007) 1.01
Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des (2011) 1.01
Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets (2010) 1.01
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther (2007) 1.01
Metformin and cancer: licence to heal? Expert Opin Investig Drugs (2010) 1.01
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother (2008) 1.00
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res (2013) 1.00
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol (2011) 1.00
The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. J Urol (2006) 1.00
Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res (2002) 1.00
Metabolic syndrome and renal disease. Int J Cardiol (2012) 0.99
Early vascular benefits of statin therapy. Curr Med Res Opin (2003) 0.99
The role of serotonin in tumour growth (review). Oncol Rep (2005) 0.99
Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke (2005) 0.99
Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem (2009) 0.99
The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit (2009) 0.99
Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol (2006) 0.99